Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 1871-1880 of 2867 for cancer

Edit search filters
  1. Compassionate Use Of Lorlatinib:PF-06463922 For Male Patient

    Rochester, MN

  2. A Study To Evaluate Tucatinib And Trastuzumab In Solid Tumors With HER2 Alterations

    Scottsdale/Phoenix, AZ, Rochester, MN

  3. A Study of the Response of Feelings, Plans, and Behaviors of People after Learning Outcomes of Genetic Research

    Rochester, MN

  4. A Study to Evaluate the Effectiveness and Safety of Remdesivir to Treat Coronavirus Disease 2019 in an Outpatient Setting

    Rochester, MN

  5. Safety And Tolerability Of Atezolizumab (ATZ) In Combination With Radium-223 Dichloride (R-223-D) In Metastatic Castrate-Resistant Prostate Cancer (CRPC) Progressed Following Treatment With An Androgen Pathway Inhibitor

    Jacksonville, FL, Rochester, MN

  6. Adding The Immunotherapy Drug Cemiplimab To Usual Treatment For People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy And Immunotherapy (An Expanded Lung-MAP Treatment Trial)

    Rochester, MN

  7. TIGER-2: A Phase 2, Open-label, Multicenter, Safety And Efficacy Study Of Oral CO-1686 As 2nd Line EGFR-directed TKI In Patients With Mutant EGFR Non-small Cell Lung Cancer (NSCLC)

    Rochester, MN

  8. A Study To Compare Venetoclax With Fulvestrant Vs. Fulvestrant Alone In Women With Locally Advanced Or Metastatic HER2-negative Cancer Who Have Progressed Or Recurred On A CDK4/6 Inhibitor

    Scottsdale/Phoenix, AZ

  9. Testing A Standardized Approach To Surgery And Chemotherapy For Type I Pleuropulmonary Blastoma Or The Addition Of An Anti-cancer Drug, Topotecan, To The Usual Treatment For Types II And III Pleuropulmonary Blastoma

    Rochester, MN

  10. A Phase 2, Multicenter, Study Of Ficlatuzumab Plus Erlotinib Versus Placebo Plus Erlotinib In Subjects Who Have Previously Untreated Metastatic, EGFR-mutated Non-small Cell Lung Cancer (NSCLC) And BDX004 Positive Label

    Rochester, MN

.

Mayo Clinic Footer